Steven Evans Lindley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Steven Evans Lindley has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Eve Bernstein Carlson
Affiliations Dissemination and Training Division, Department of Veterans Affairs, National Center for Posttraumatic Stress Disorder, VA Palo Alto Health Care System, Menlo Park, California, United States of America, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, United States of America
3 shared publications Alan Schatzberg
Department of Psychiatry, Stanford University School of Medicine, Stanford, California
1 shared publicationCarolyn J. Greene
VA National Center for PTSD, Dissemination & Training Division
1 shared publication- Craig S. Rosen
National Center for PTSD, Dissemination and Training Division, VA Palo Alto Healthcare System, 795 Willow Rd, Menlo Park, CA, 94025, United States of America; Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Rd, Palo Alto, CA, 94305, United States of America
1 shared publication Delilah Noronha
Veterans Affairs Palo Alto Health Care System, Menlo Park, California
1 shared publicationHolly Cacciapaglia
Veterans Affairs Palo Alto Health Care System, Menlo Park, California
1 shared publication
Latest Publications
- 25 August 2025
- Published by Springer Nature
- p. 389-395
How to Conceptualize a Research Project
- 29 April 2014
- Published by Springer Nature in Academic Psychiatry
- Vol. 39 (1) , 114-118
A Pilot Program in Telepsychiatry for Residents: Initial Outcomes and Program Development
- 29 April 2014
- Published by Springer Nature in Academic Psychiatry
- Vol. 39 (1) , 114-118
A Pilot Program in Telepsychiatry for Residents: Initial Outcomes and Program Development
- 1 February 2014
- Published by Wolters Kluwer Health in Journal of Nervous & Mental Disease
- Vol. 202 (2) , 91-96
Psychotic-like Experiences, Symptom Expression, and Cognitive Performance in Combat Veterans With Posttraumatic Stress Disorder
Apparent psychotic symptoms are often associated with posttraumatic stress disorder (PTSD), but these symptoms are poorly understood. In a sample of 30 male Vietnam combat veterans with severe and chronic PTSD, we conducted detailed assessments of psychotic symptom endorsement, insight, symptom severity, neurocognitive function, and feigning. Two thirds of the subjects endorsed a psychotic item but did not believe that the experiences were real. Those endorsing psychotic items were higher in PTSD severity, general psychopathology, and dissociation but not depression, functional health, cognitive function, or feigned effort. Severity of psychotic symptoms correlated with dissociation, combat exposure, and attention but not PTSD, depression, or functional health. Those endorsing psychotic items scored higher on a screen but not on a detailed structured interview for malingering. Endorsement of psychotic experiences by combat veterans with PTSD do not seem to reflect psychotic symptoms or outright malingering.
- 1 February 2014
- Published by Wolters Kluwer Health in Journal of Nervous & Mental Disease
- Vol. 202 (2) , 91-96
Psychotic-like Experiences, Symptom Expression, and Cognitive Performance in Combat Veterans With Posttraumatic Stress Disorder
Apparent psychotic symptoms are often associated with posttraumatic stress disorder (PTSD), but these symptoms are poorly understood. In a sample of 30 male Vietnam combat veterans with severe and chronic PTSD, we conducted detailed assessments of psychotic symptom endorsement, insight, symptom severity, neurocognitive function, and feigning. Two thirds of the subjects endorsed a psychotic item but did not believe that the experiences were real. Those endorsing psychotic items were higher in PTSD severity, general psychopathology, and dissociation but not depression, functional health, cognitive function, or feigned effort. Severity of psychotic symptoms correlated with dissociation, combat exposure, and attention but not PTSD, depression, or functional health. Those endorsing psychotic items scored higher on a screen but not on a detailed structured interview for malingering. Endorsement of psychotic experiences by combat veterans with PTSD do not seem to reflect psychotic symptoms or outright malingering.
- 18 October 2010
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1208 (1) , 104-113
Monitoring mental health treatment acceptance and initial treatment adherence in veterans
Identifying factors that influence mental health outcomes in veterans can aid in the redesign of programs to maximize the likelihood of early resolution of problems. To that end, we examined demographic and clinical process data from 2,684 veterans who scored positive on a mental health screen. We investigated this data set for patterns and possible predictors of mental health referral acceptance and attendance. The majority of patients had not received mental health treatment within the last two years (76%). Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) were more likely to accept a mental health referral for depression but were equally likely to attend a mental health visit as other era veterans. Decreased acceptance was associated with provider type and contact method, clinic location, depression only, and specific age ranges (65–74). Among those who accepted a referral, decreased attendance was associated with clinic location, depression only, and retirement. No variables predicted OEF/OIF acceptance/attendance. In conclusion, our findings illustrate the importance of close, continual monitoring of clinical process data to help reveal targets for improving mental health care for veterans.
- 18 October 2010
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1208 (1) , 104-113
Monitoring mental health treatment acceptance and initial treatment adherence in veterans
Identifying factors that influence mental health outcomes in veterans can aid in the redesign of programs to maximize the likelihood of early resolution of problems. To that end, we examined demographic and clinical process data from 2,684 veterans who scored positive on a mental health screen. We investigated this data set for patterns and possible predictors of mental health referral acceptance and attendance. The majority of patients had not received mental health treatment within the last two years (76%). Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) were more likely to accept a mental health referral for depression but were equally likely to attend a mental health visit as other era veterans. Decreased acceptance was associated with provider type and contact method, clinic location, depression only, and specific age ranges (65–74). Among those who accepted a referral, decreased attendance was associated with clinic location, depression only, and retirement. No variables predicted OEF/OIF acceptance/attendance. In conclusion, our findings illustrate the importance of close, continual monitoring of clinical process data to help reveal targets for improving mental health care for veterans.
- 1 December 2007
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (6) , 677-681
A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation Topiramate for Chronic Combat-Related Posttraumatic Stress Disorder
Topiramate, a novel anticonvulsant, has been reported to rapidly reduce symptoms of posttraumatic stress disorder (PTSD) in an open-label trial. The present study was designed as a test of topiramate's efficacy as adjunctive therapy in a 7-week, randomized, double-blind, placebo-controlled trial. Forty male veterans with PTSD in a residential treatment program were randomized to flexible-dose topiramate or placebo augmentation. The primary outcome measures were PTSD symptom severity and global symptom improvement. Baseline Clinician-Administered PTSD Scale scores were 62.1 +/- 13.9 for placebo and 61.0 +/- 22.2 for topiramate. There was a high dropout rate from the study (55% topiramate; 25% placebo), with 40% of topiramate and 10% of placebo dropping because of adverse events (AEs). No significant treatment effects of topiramate versus placebo were observed for the primary treatment outcomes. Subjects reporting central nervous system-related AEs and with higher baseline severity of depression were more likely to discontinue because of AEs. Primary outcome measures failed to demonstrate a significant effect for topiramate over placebo; however, high dropout rate in the treatment group prohibits definitive conclusions about the efficacy of topiramate in this population.
- 1 December 2007
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (6) , 677-681
A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation Topiramate for Chronic Combat-Related Posttraumatic Stress Disorder
Topiramate, a novel anticonvulsant, has been reported to rapidly reduce symptoms of posttraumatic stress disorder (PTSD) in an open-label trial. The present study was designed as a test of topiramate's efficacy as adjunctive therapy in a 7-week, randomized, double-blind, placebo-controlled trial. Forty male veterans with PTSD in a residential treatment program were randomized to flexible-dose topiramate or placebo augmentation. The primary outcome measures were PTSD symptom severity and global symptom improvement. Baseline Clinician-Administered PTSD Scale scores were 62.1 +/- 13.9 for placebo and 61.0 +/- 22.2 for topiramate. There was a high dropout rate from the study (55% topiramate; 25% placebo), with 40% of topiramate and 10% of placebo dropping because of adverse events (AEs). No significant treatment effects of topiramate versus placebo were observed for the primary treatment outcomes. Subjects reporting central nervous system-related AEs and with higher baseline severity of depression were more likely to discontinue because of AEs. Primary outcome measures failed to demonstrate a significant effect for topiramate over placebo; however, high dropout rate in the treatment group prohibits definitive conclusions about the efficacy of topiramate in this population.